Primary analyses from this phase 3 clinical trial of the investigational, subcutaneous infusion of levodopa/carbidopa (LD/CD) (ND0612) showed that treatment in doses of up to 720 mg/90 mg per day, supplemented with oral levodopa provided almost 2 additional hours per day of “Good On” time without troublesome dyskinesia compared with immediate-release levodopa/carbidopa (IR-LD/CD) at week 12.
Subcutaneous combination therapy improves... - Cure Parkinson's
Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Mucuna pruriens in Parkinson’s
Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study
R...
Liquefy your L-dopa
The following method for liquefying L-dopa has been shown to have faster on time with less...
Significance of Newly Approved IPX203 for Parkinson Disease
Earlier this month, the FDA approved Amneal Pharmaceuticals’ investigational agent IPX203, an oral...
Mucuna Pruriens in Parkinson's disease, dosages and effects, A double-blind, randomized, controlled, crossover human study (2017)
Mucuna pruriens in Parkinson disease. A double-blind, randomized, controlled, crossover study...
Opicapone helps prolong plasma levodopa levels in patients with Parkinson’s
- Once-daily opicapone 50 mg with carbidopa/levodopa helped achieve and maintain plasma...
Related Posts
Minimum of 70 mg Carbidopa daily???- UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment
Can Levodopa Contribute to Gut Dysbiosis via Increased Gut Inflammation and More Dysbiosis? The Study Below Suggests It Can
Suggestions on this mucuna dosage calculation
Clinical Trial Highlights – an update on previously reviewed trials (Phase 3 in focus)
